Assessment first
Evidence-aware
Safety focused
Women’s Health Clinic FAQ
What is the clinical evidence supporting polynucleotide therapy for improving endopelvic connective tissue strength?
Procedural and emerging options for stress urinary incontinence can sound technically convincing, but suitability depends on the exact leakage mechanism, tissue health, urinary symptoms, previous treatments and safety checks.
Direct answer
Polynucleotide therapy is discussed for tissue hydration, repair signalling and extracellular-matrix support, but direct evidence for strengthening endopelvic connective tissue in SUI is limited. The safest wording is that this is an emerging area, not an established continence treatment. Patients should understand what is theoretical, what is studied and what remains uncertain.
The safest discussion separates what a treatment is designed to do, what evidence supports it, what remains uncertain and which symptoms should delay treatment or prompt urgent review.
Educational only. This page is educational and does not replace individual assessment. Results vary. Not a cure.
SUI assessment
At a glance
These are the key clinical points to understand before considering treatment.
At a glance
Clinical summary
Evidence status
Regenerative SUI claims remain emerging or investigational.
Biology
Signalling and tissue-repair rationale is not the same as proven repair.
Selection
Assessment should consider established options first.
Safety
Avoid promises of sphincter regeneration or routine clinical benefit.
Important safety note
Seek medical advice promptly for inability to pass urine, painful bladder fullness, fever, blood in urine, severe pelvic pain, recurrent infection symptoms, new neurological symptoms or postmenopausal bleeding.
Evidence
Suitability
Consent
Review
Detailed answer
Detailed answer
PRP, polynucleotides, stem cells and exosomes are often discussed through biological plausibility, but patient claims must stay grounded.
Clinical context
Laboratory or early clinical rationale does not prove repaired urethral sphincter function.
Tissue
Safety
Evidence
What it is meant to do
PRP, polynucleotides, stem cells and exosomes are often discussed through biological plausibility, but patient claims must stay grounded.
Why selection matters
Laboratory or early clinical rationale does not prove repaired urethral sphincter function.
Evidence limits
Patients should understand whether a treatment is established, off-label, experimental or evidence-limited.
Safety and review
The final page should avoid implying that natural, autologous or regenerative language means safer or more effective.
What this means in practice
A responsible SUI page should explain the proposed mechanism without teaching procedural method or technical operating detail.
If symptoms suggest infection, retention, pain, bleeding or mixed incontinence, treatment should pause until the cause is assessed.
Patient safety
Why this distinction matters
Bulking, energy devices and regenerative options are not interchangeable, and each has different evidence, consent and safety issues.
It clarifies mechanism
Coaptation, tissue remodelling, sphincter weakness and support loss describe different clinical problems.
It protects consent
Patients need to know what is established, what is emerging and what cannot be promised.
It checks safety
Infection, retention, pain, bleeding and tissue fragility can change whether treatment should proceed.
It prevents overclaiming
Technical language should never imply promised dryness, proven regeneration or device superiority.
A clinician-led decision
The safest plan balances symptom burden, diagnosis, alternatives, likely benefit, evidence limits and aftercare.
This is especially important when treatment is invasive, energy-based or regenerative.
Considerations
What to consider
Before treatment, consider diagnosis, previous conservative care, bladder emptying, infection risk, tissue quality, pain, prolapse and realistic goals.
Consultation priorities
Assessment should confirm the leakage mechanism and whether established conservative or procedural options are more appropriate.
Consent
Aftercare
Escalation
Before treatment
Assessment should confirm the leakage mechanism and whether established conservative or procedural options are more appropriate.
Consent discussion
The consent discussion should separate theory, early evidence, uncertainties and alternatives.
Aftercare
Any treatment plan should include review points and a clear explanation of non-response.
If symptoms persist
If claims sound like certain repair, the wording should be made safer before publication.
Practical expectations
Response varies; treatment decisions should be reviewed against leakage triggers, comfort, emptying, infection symptoms and quality-of-life impact.
Costs, access and treatment details should be confirmed directly with the clinic before booking.
Common concerns and myths
Common misconceptions
These points help keep procedural and emerging SUI treatments realistic.
Myth: regenerative means proven repair
Reality: biological plausibility is not the same as clinical proof.
Myth: autologous or natural means without risk
Reality: injections and tissue interventions still need consent and governance.
Myth: early studies prove routine benefit
Reality: evidence quality, follow-up and patient selection matter.
Evidence and advertising
Clinical claims should not outrun the quality of evidence, especially for energy and regenerative treatments.
Alternatives
Supervised PFMT, pessary support, bulking, surgery or specialist referral may each fit different patients.
Safety checklist
Safety checklist
Use these checks before relying on procedural, energy-based or regenerative treatment claims for SUI.
Is the diagnosis clear?
Stress, urge, overflow, infection and retention symptoms should be separated before treatment.
Has suitability been assessed?
Mechanism, tissue health, previous treatment, red flags and expectations all affect suitability.
Are red flags absent?
Seek medical advice promptly for inability to pass urine, painful bladder fullness, fever, blood in urine, severe pelvic pain, recurrent infection symptoms, new neurological symptoms or postmenopausal bleeding.
Is follow-up planned?
Patients should know how response, side effects and next steps will be reviewed.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, infection and retention symptoms are absent, and expectations are realistic.
No red flags
Review plan
Reasons to pause
Seek medical advice promptly for inability to pass urine, painful bladder fullness, fever, blood in urine, severe pelvic pain, recurrent infection symptoms, new neurological symptoms or postmenopausal bleeding.
Infection
Bleeding
When to escalate
When to seek medical help
Some urinary symptoms need prompt review before or after SUI procedures.
Use NHS 111 online
Unable to pass urine
Inability to pass urine or painful bladder fullness after a procedure needs prompt clinical advice.
Infection symptoms
Fever, burning with systemic symptoms, worsening pelvic pain or feeling unwell should be assessed.
Bleeding or severe pain
Blood in urine, unexplained bleeding, severe pelvic pain or worsening discomfort should not be ignored.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware continence information.
NICE NG123 urinary incontinence recommendations
NICE anchors established SUI care and evidence-aware escalation.
NHS urinary incontinence treatment
NHS gives public context for conservative and procedural urinary incontinence treatment.
FDA regenerative medicine overview
FDA terminology helps keep regenerative claims cautious and distinct from proven benefit.
Next step
Book a continence consultation
A consultation can clarify the SUI mechanism, review safer established options, and decide whether a procedural or emerging treatment is appropriate.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 270 curated sources. Additional reviewed material included professional society guidance, peer-reviewed clinical papers, evidence reviews, clinical trial records; duplicate and low-relevance records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
